Cellular Biomedicine Group (CBMG)

Oncology Corporate Profile

Stock Performance

17.9400
-0.1200

HQ Location

530 University Avenue, Ste 17
Palo Alto, CA 94301

Company Description

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG?s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.

Website: http://www.cellbiomedgroup.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CD40LGVAXimmunotherapyNon Small Cell Lung Cancer (NSCLC)II
Unnamedtumor stem cell specific dendritic cell (TC-DC) therapyHepatocellular carcinoma (HCC)I

View additional information on product candidates here »

Source


http://www.cellbiomedgroup.com

Recent News Headlines

Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders

3/21/2017 12:01 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., March 21, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem ...

Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress

3/14/2017 10:00 am

[GlobeNewswire] - Embarked On GMP Expansion To Become One Of The Largest In-House CAR-T Manufacturers in Terms of Capacity Amongst Leading Biopharmaceutical Companies In The World Commenced Two CAR-T Phase I Clinical Trials ...

Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.

2/27/2017 01:00 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Feb. 27, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem ...

Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017

2/7/2017 01:03 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Feb. 07, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem ...

Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China

1/9/2017 11:01 am

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 09, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell ...

Cellular Biomedicine Group (CBMG) to Present at the 9th Annual Biotech Showcase in San Francisco

1/4/2017 01:00 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 04, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell ...

Cellular Biomedicine Group (CBMG) Expands Cell Production With Capacity to Produce CAR-T Therapies to Treat 10,000 Cancer Patients Annually

1/3/2017 01:00 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Jan. 03, 2017-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell ...

Cellular Biomedicine Group Announces Three-Month Interim Safety Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis

12/9/2016 01:00 pm

[GlobeNewswire] - -No Serious Adverse Events Observed-. SHANGHAI, China and CUPERTINO, Calif., Dec. 09, 2016-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective immunotherapies ...

Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China

11/29/2016 12:01 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Nov. 29, 2016-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell ...

Cellular Biomedicine Group to Present at the 2016 World Stem Cell Summit

11/28/2016 12:03 pm

[GlobeNewswire] - SHANGHAI, China and CUPERTINO, Calif., Nov. 28, 2016-- Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell ...